Latham Steers $160M Debut Of Allergy Biotech Aimmune
Venture capital-backed Aimmune Therapeutics Inc., led by Latham & Watkins LLP, saw its shares soar in its trading debut Thursday after the severe allergy biotech topped expectations with a $160 million...To view the full article, register now.
Already a subscriber? Click here to view full article